Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch
US FDA Cleared KRAS G12C Inhibitor For Second-Line NSCLC
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.
